US DEA, finally, schedules Eisai's epilepsy drug
This article was originally published in SRA
Executive Summary
With the issuance of a final rule on 2 December, the US Drug Enforcement Administration placed Eisai’s epilepsy drug Fycompa (perampanel), including its salts, isomers and salts of isomers, into Schedule III of the Controlled Substances Act1 – an action that the company had to fight for.